Xilio Therapeutics, Inc. (XLO) company profile
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
About Xilio Therapeutics
Pharmaceutical Preparations, SIC 2834
Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer treatment. Using proprietary protein engineering and masking technology, the company designs biologic therapies, including masked multi-specific molecules, engineered to activate selectively within the tumor microenvironment through tumor-specific proteases. These therapies aim to deliver localized therapeutic activity while minimizing the toxicities commonly caused by systemic exposure. The company develops programs for individuals living with cancer and engages in strategic collaboration and licensing agreements with biopharmaceutical partners, including Gilead Sciences and AbbVie.
The company operates its principal executive offices in Waltham, Massachusetts. Its activities also involve research, development, and manufacturing collaborations with global partners, including manufacturing and research operations conducted through WuXi Biologics in China. Corporate governance and business operations are conducted under Delaware jurisdiction.
Summary of the business section of Xilio Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Xilio Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 828 Winter Street 02451
- Phone
- (617) 833-1027
- Website
- xiliotx.com
- Employees
- 76, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- XLO
- Exchange
- Nasdaq
- IPO date
- Oct 22, 2021
- Shares outstanding
- 6M, Mar 18, 2026
- Public float
- $34.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-14 reverse, Mar 16, 2026
- SEC CIK
- 1840233
- CUSIP
- 28422T209
- ISIN
- US28422T2093
- FIGI
- BBG00M4D4X92
- Share class FIGI
- BBG00M4D4XC8
- EIN
- 85-1623397
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rene Russo | PRESIDENT AND CEO, Director | 325,422 |
| Yariv Houvras | CHIEF MEDICAL OFFICER | – |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 6,371 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 33,250 |
| Daniel J. Curran | Director | – |
| Yuan Xu | Director | – |
| Robert W. Ross | Director | – |
| James Samuel Shannon | Director | 10,000 |
| Aoife Brennan | Director | – |
| Sara Bonstein | Director | – |
| Akintunde Olatokumbo Bello | Director | – |
| Cheryl R. Blanchard | Director | – |
| Paul J. Clancy | Director | – |
| Christina Rossi | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| René Russo, Pharm.D. President and Chief Executive Officer | $643.70K | $128.74K | $5.29M | $371.74K | $14.00K | $6.45M | +343% |
| Christopher Frankenfield Chief Financial and Operating Officer | $533.10K | $106.62K | $2.29M | $287.87K | $14.00K | $3.23M | +212% |
| Katarina Luptakova, M.D. Chief Medical Officer | $481.30K | – | $1.51M | $196.37K | $14.00K | $2.20M | +194% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 22, 2021
- Offer price
- $16.00
- Securities offered
- 7,353,000
- Gross proceeds
- $117.65M
- Exchange
- Nasdaq
- First trading day
- Oct 22, 2021
- First-day close
- $16.00-0.0%
- Lock-up ends (est.)
- Apr 20, 2022
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 76 full-time employees, including 30 employees with M.D., Pharm.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 3, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 28, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 8, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 19, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 22, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 18, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?